Iovance Biotherapeutics Inc (IOVA) soared 0.57 in the last month: It’s impossible to believe the numbers

A new trading day began on Monday, with Iovance Biotherapeutics Inc (NASDAQ: IOVA) stock price up 0.57% from the previous day of trading, before settling in for the closing price of $1.75. IOVA’s price has ranged from $1.64 to $12.51 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Meanwhile, its annual earnings per share averaged 12.10%. With a float of $271.58 million, this company’s outstanding shares have now reached $333.93 million.

Let’s look at the performance matrix of the company that is accounted for 838 employees. In terms of profitability, gross margin is 19.2%, operating margin of -187.5%, and the pretax margin is -178.03%.

Iovance Biotherapeutics Inc (IOVA) Insider Updates

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Iovance Biotherapeutics Inc is 18.67%, while institutional ownership is 64.00%. The most recent insider transaction that took place on May 23 ’25, was worth 9,743. In this transaction Chief Regulatory Officer of this company bought 5,600 shares at a rate of $1.74, taking the stock ownership to the 206,852 shares. Before that another transaction happened on May 14 ’25, when Company’s Interim CEO & General Counsel bought 25,000 for $1.69, making the entire transaction worth $42,250. This insider now owns 374,646 shares in total.

Iovance Biotherapeutics Inc (IOVA) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 12.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 47.62% during the next five years compared to 4.17% growth over the previous five years of trading.

Iovance Biotherapeutics Inc (NASDAQ: IOVA) Trading Performance Indicators

Here are Iovance Biotherapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.76.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.23, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -0.77 in one year’s time.

Technical Analysis of Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (NASDAQ: IOVA) saw its 5-day average volume 10.94 million, a negative change from its year-to-date volume of 11.61 million. As of the previous 9 days, the stock’s Stochastic %D was 40.47%. Additionally, its Average True Range was 0.21.

During the past 100 days, Iovance Biotherapeutics Inc’s (IOVA) raw stochastic average was set at 2.01%, which indicates a significant decrease from 35.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.97% in the past 14 days, which was lower than the 122.97% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $2.8242, while its 200-day Moving Average is $6.8169. Nevertheless, the first resistance level for the watch stands at $1.8063 in the near term. At $1.8525, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.8957. If the price goes on to break the first support level at $1.7169, it is likely to go to the next support level at $1.6737. Assuming the price breaks the second support level, the third support level stands at $1.6275.

Iovance Biotherapeutics Inc (NASDAQ: IOVA) Key Stats

With a market capitalization of 587.73 million, the company has a total of 333,934K Shares Outstanding. Currently, annual sales are 164,070 K while annual income is -372,180 K. The company’s previous quarter sales were 49,320 K while its latest quarter income was -116,160 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.